Product Image
Myco-α vaccine
Components
- Mycoplasma hyopneumoniae inactivated antigen
- Recombinant P97 protein derived from Mycoplasma hyopneumoniae
- IMS1313
Efficacy and effectiveness
- Prevention and Symptom Relief of Swine Mycoplasma Pneumonia
- Excellent humoral and cell-mediated immunity in response to Swine Pneumonia
- Confirmation of significant reduction in lung lesions by Mhp
- Provides high safety without any side effects
Usage and Capacity
- 1 injection of 2mL into a pig of 1 weeks or older
- Shake enough vaccine before use
Mycoalpha
- Myco-α
- High-quality vaccine excellent in preventing Swine Mycoplasma Pneumonia
- A new concept of high-efficacy vaccine containing P97, an adhesin of Mhp, as the form of recombinant proteins
- Safe and effective vaccine to reduce clinical symptoms and lung lesion and prevent early infection of Swine Mycoplasma Pneumonia
Product Overview
| Product Name | Myco-α |
|---|---|
| Time for vaccination | 1 vaccination to pigs over 3 weeks old |
| Vaccination method | Injection once by Intramuscular injection with 2mL of vaccine |
| Efficacy and Effectiveness | Prevention of Swine Mycoplasma Pneumonia |
Product Properties
- Prevention of initial infection of Mhp by inducing antibody to Mhp adhesin (P97)
- Excellent defense for both symptoms and infection
- Defense effects that induce both humoral and cell-mediated immunity
- Containing high titer Mhp and recombinant P97
Symptoms of Porcine Mycoplasma Pneumonia
- Infectious diseases that have very high transmission power and cause chronic wasting pneumonia〮 Mycoplasma hyopneumoniae (Mhp) causes Pneumonia destroying respiratory cilia, inducing secondary
- infection of respiratory pathogens of PRRSV and Pasteurella through collapse of the host's defense mechanism against respiratory infections (Primary cause of Porcine Respiratory Disease Complex)
Product Distinct Value
- Verified excellence and advantage in comparison test with global existing commercial vaccine products
- INNOVAC Myco-α vaccine verified excellence in efficacy
- Confirming excellent antibody induction after vaccination
- 86% clearance of Mhp in lungs after vaccination
- 60% reduction in lung lesions after vaccination